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Background: We evaluated the feasibility and safety of new aortic valved stents in transcatheter aortic valve
implantation (TAVI) using retrograde approach by in vitro testing and animal implantation.
Materials and Methods: The fluid passing test, expanding and releasing tests, static and releasing tests in tube
were performed for new valved stents. Transvalvular pressure gradient, effective orifice area, pre-implantation and
post-implantation regurgitant volume for the new stents were detected. Then, the new stents were implanted in
six pigs using retrograde approach. These pigs were euthanized 12 h after the implantation for anatomic
evaluation.
Results: In vitro tests showed that the closure of the new stents leaflets were effective, and stents could be
released through catheter, then expanded completely and fixed fast in the tube. The coronary artery flow rates did
not changed significantly after implantation (P > 0.05), while aortic regurgitant volumes were obviously reduced
(P < 0.05). No significant difference in the transvalvular pressure gradient and effective orifice area of the new stents
implanted within or above the valve leaflets was found (P > 0.05). In vivo experiments indicated that TAVI was
successfully performed in six pigs using retrograde approach. However, one pig was died 10 h after the
implantation since the stent was not expanded completely. The leaflets in stents were opening well and no valvular
regurgitation was observed in the other five pigs. And thrombosis was not found.
Discussion and Conclusion: The new type of aortic valved stent designed in this study was characterized with
good stability and could avoid the impact caused by valve leaflets on the coronary artery.
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Health care systems could be affected by cardiovascular
disease (CVD) which is the main cause of death world-
wide, accounting for 7.25 million deaths per year accord-
ing to the report from the World Health Organization
[1,2]. Meanwhile, diagnosis and treatment for diseases of
the aortic valve are very essential since the aortic valve
disease has high incidence and seriously threats the
health and life of people. On the other hand, untreated
diseases of aortic valve can ultimately lead to severe in-
fection, heart failure, and even sudden death [3].
Currently, one of the most cardiac operations and
standard therapies for aortic valve disease is open chest
surgical aortic valve replacement which has mature* Correspondence: wangyongwu993@sohu.com
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reproduction in any medium, provided the orprocedures and good effects [4]. However, the surgical
aortic valve replacement has some defects, such as se-
vere trauma, extracorporeal circulation, long recovery
time and long-term anticoagulation. A high prevalence
of comorbidities is occurred in the elderly patients with
symptomatic aortic valve stenosis [4]. What’s more, the
common comorbidities including advanced age, previous
cardiac surgery, left ventricular dysfunction, heart failure,
pulmonary disease and renal insufficiency are known to
be responsible for the high periprocedural and postproce-
dural risk of mortality and morbidity for patients [5,6].
And almost one third of patients with aortic valve stenosis
who have these above comorbidities are rejected for sur-
gery [7,8]. Therefore, it is still a great challenge for medical
technicians to treat the aortic valve patients with high risk
effectively.. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ation (TAVI) was first reported by Anderson et al. [9]. A
new artificial aortic valve prosthesis which was prepared
by mounting an expandable stent with a porcine aortic
valve was implanted without thoracotomy or extracor-
poral circulation by the transluminal catheter technique
indicating that transluminal catheter technique could be
used for the implantation of artificial aortic valves in
closed chest animals [9]. And Cribier et al. have reported
that the first human implantation was performed in a
man aged 57 with calcific aortic stenosis and many other
associated noncardiac diseases [10]. Percutaneously im-
planted heart valve was successfully implanted within
the native aortic valve with many diseases, with accurate
positioning and a mild paravalvular aortic regurgitation,
no impairment of the mitral valve function or the coron-
ary artery blood flow was observed [10].
Though the success rate and curative effect for the
TAVI is gradually increasing, the mortality rate of high-
risk patients could still be up to approximately 20%
within 30 days of the surgery [4,11,12]. However, TAVI
has a series of advantages, such as minimally invasion,
less physical damage and rapid postoperative recovery.
Therefore, TAVI has good development and applied pros-
pects especially in high-risk patients who have contraindi-
cations for surgical aortic valve replacement and it is
increasingly being used to treat severe aortic stenosis in
patients with high operative risk [13,14]. Despite the fact
that TAVI has entered the mainstream as a viable treat-
ment option for patients with symptomatic, severe aortic
stenosis who are at prohibitively high surgical risk, there
are still many problems associated with stent implantation
including accurate and stable valve positioning, disorder
of mitral valve function, risk of coronary artery obstruc-
tion and paravalvular leak [15-17]. Hence, the application
of TAVI need to be further studied and developed.
In our study, a new type of aortic valve stent was made
according to the anatomy parameters of porcine aorticFigure 1 The animal preparation for the implantation. The healthy aduroot and porcine pericardium valves were sutured with
the distal end of self-expandable stent. Furthermore, we
evaluated the feasibility, safety and efficacy of the new
type aortic valve stent in TAVI using retrograde implant-




A total of six healthy adult pigs (Figure 1A) of either
gender weighing 15–21 kg were enrolled (Songjiang
Experimental Animal Field, Shanghai, China). The study
was performed after the pigs were allowed to acclimate
for 1 week in the Animal Experiment Center of Tongji
University. Anesthesia for pigs was initiated by intramus-
cular injection of 10 mg/kg ketamine (Jiangsu Hengrui
Medical Co. Ltd, China), followed by intravenous in-
jection of 10 ml of 2.5% pentobarbital sodium (Sinopharm
Chemical Reagent Co. Ltd, China). Animal care and use
was in accordance with the guidelines established by the
Animal Ethics Committee of Tongji University.
Manufacture of the new type of aortic valved stent
The module of aortic valved stent (Figure 2A) was made
according to the measured anatomy parameters and
morphological characteristics of porcine aortic root
(Figure 1B). The self-expandable stent with the diam-
eter of 20–26 mm was made by 0.2 mm super malle-
able nitinol wire (Electric Titanium Factory of Jintai in
Baoji City, Shaanxi, China) according to the method of
sine curve. And the manufacture of self-expandable stent
was accomplished (Figure 2B, C) after the procedures of
heat treatment, heat setting (400-500°C, twice), acid pick-
ling, cleaning, drying and inspection.
Fresh porcine pericardia (Songjiang Experimental
Animal Field, Shanghai, China) with uniform thickness
and fiber were selected and immersed in 0.6% glutaralde-
hyde for 36 h (pH = 7.4) after acellular disposal by 0.01%lt pig (A); the aortic inner diameter of experimental pig (B).
Figure 2 Manufacture of the new type of aortic valved stent. The module of aortic valved stent (A); side view of the self- expandable stent
(B); top view of the self- expandable stent (C); side view of the new aortic valved stent (D); top view of the new aortic valved stent (E). The old
aortic valved stents in a side view (F) and a top view (G).
Cai et al. Journal of Cardiothoracic Surgery 2013, 8:210 Page 3 of 9
http://www.cardiothoracicsurgery.org/content/8/1/210trypsin solution. Then, the decellularized pericardia were
immersed in the 2% L-glutamic acid solution for 24 h to
remove the toxicity of glutaraldehyde and sutured to the
distal end of self-expandable stent by 6–0 PROLENE
(Shanghai Pudong Jinhuan Medical Products Co. Ltd,
China). The stents were placed in the fixing solution for
one day after the sinuses of the valve were pressed with
medical cotton balls. Then, the manufactured novel aortic
valved stents (Figure 2D, E) were preserved in 70% ethanol
and washed with physiological saline three times before
use. Meanwhile, the old aortic valved stents with the cylin-
drical shape were also manufactured (Figure 2F, G).
Performance of aortic valved stents in vitro
The valved stents were delivered to the left ventricle of
the isolated heart from 3–4 months old miniature pig
(Songjiang Experimental Animal Field, Shanghai, China)
by ascending aorta and placed in the aortic valve. Then,
the aortic valved stents were released and water was
injected to observe the valvular competence and coron-
ary flow rates (Figure 3).
The fluid passing test, expanding and releasing tests,
static and releasing tests in tube were performed for new
aortic valved stents by Sarns 5200 extracorporeal circu-
lation at 40–120 mmHg (Sarns, America). In the fluidpassing test, the closure, open and regurgitation of all
valved stents were observed when uniform flow rushed
to the stents in the opposite or same direction. In the
expanding and releasing tests, the valved stents were re-
leased into the physiological saline at 37°C. Then, the
expanding degree and rate were observed. For the static
and releasing tests, the polyvinyl chloride (PVC) tube
(Shanghai Xiangsheng Medical Instrument Co. Ltd,
China) whose inner diameter was matched with that of
the valved stent was selected. The stents were implanted
in the tube by simulating TAVI at 37°C (thermostatic
water tank, Sarns, America) via a catheter (Shanghai
Pujiang Medical New Material Co. Ltd, China). The tube
was filled with water continuously and stopped filling
when the height of water surface was up to 150 cm. The
fixation, flow direction, leakage, degree of closure and
open of valved stents were observed. Transvalvular pres-
sure gradient for the new type of valved stents (n = 6)
implanted within the valve leaflets or in ascending aorta
were measured under the flow rate of 1–9 L/min in the
physiological saline at 37°C. Meanwhile, effective orifice
areas for the new type of valved stents were also detected by
the method of Doppler ultrasound. The pre-implantation
and post-implantation regurgitant volume of new valved
stents under 40–120 mmHg were detected. The static
Figure 3 The static and releasing tests of aortic valved stent in PVC tube.
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valved stents under 40–120 mmHg were compared.
Implantation of aortic valved stents in vivo
The experimental pigs were placed on the Model JL-1A
operating table (Medical Equipment Factory of Shanghai
Medical Instruments Co. Ltd, China) with supine pos-
ition and hair was removed from the precordial region.
After the skin of the inguinal region was sterilized, a
5 cm incision was made through the right inguinal skin
and subcutaneous tissue. Then, the right femoral artery
was subsequently exposed and punctured with a 7-French
(F) leak-proof sheath. Heparin (100U/kg, Sinopharm
Chemical Reagent Co. Ltd, China) was introduced via
the sheath. A 6 F pigtail catheter was introduced
through the right femoral artery sheath, and imaging of
the left ventricle was performed by using digital subtrac-
tion angiography (DSA) apparatus (GE, America). TheFigure 4 Radiography of valved stent. The radiographs of aortic valvedradiography of valved stent in the ascending aorta was
shown in Figure 4.
Then, the positions of aortic valve and coronary artery
were identified according to the imaging results. After
the inner diameter of the ascending aorta was mea-
sured, the aortic valve was punctured. A balloon cath-
eter (4.0 × 15 mm) was place in the crevasse of the aortic
valve via a steel guide wire (2.5 m). The balloon catheter
was pushed out after the crevasse of the aortic valve was
enlarged by compressing the balloon dilator. The ascend-
ing aortic angiography was performed to confirm the
aortic valve incompetence and echocardiography was
conducted to measure the regurgitant volume.
New type aortic valved stents with the diameter of
2 mm larger than the measured ascending aorta were se-
lected. The delivery route was established by introducing
a steel guide wire into the left ventricle via the pigtail
catheter. After the pigtail catheter was removed, a 12-stent in the ascending aorta (A) and during implantation (B).
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ployed into the ascending aorta at the top of the coron-
ary artery via a guide wire. The expandable stub and
steel guide wire were then removed and the 14 F sheath
carrying the valve stent was connected with the delivery
sheath. The stent was inserted into the delivery sheath
positioned under the DSA apparatus to the previously
marked position of the ascending aorta. After it was
confirmed that the stent had been delivered to the opti-
mal position, the delivery sheath was retracted to release
the stent. The delivery sheath was subsequently removed
and the right femoral artery was sutured.
Then, echocardiography and ascending aortic angiog-
raphy were performed to observe aortic valvular regurgi-
tation by deploying a pigtail catheter via the left femoral
artery. The catheter and right femoral artery sheath
were removed. All pigs received postoperative intra-
muscular injections of penicillin (80,000,000 U, North
China Pharmaceutical Co. Ltd) and subcutaneous in-
jections of heparin (2,500 IU).
Statistical analysis
Statistical analysis was performed by the SPSS version
12.0 statistical software. The measurement data were
expressed as mean ± standard deviation and analyzed by
T-test. There is significantly statistical difference when
P <0.05.
Results
Properties of aortic valved stents in vitro
In vitro performance tests, the closure of the valved
stent leaflets were effective, and all fluid flows were not
restricted in the opposite direction. The valved stents
could be released through catheter, then expanded com-
pletely and could fix fast in the tube (Figure 3).
The coronary flow rates pre-implantation and post-
implantation were shown in Table 1. The left coronary
artery flow rate decreased from 25.38 ± 5.50 ml/s to
19.71 ± 4.80 ml/s (P = 0.0000) and the right decreased
from 21.30 ± 5.41 ml/s to 17.74 ± 4.10 ml/s (P = 0.0001)
when the new type of aortic valved stents were released
within the native valve leaflets. The left coronary artery
flow rate decreased from 27.71 ± 6.28 ml/s to 27.58 ±
6.16 ml/s (P = 0.07426) and the right decreased fromTable 1 The coronary flow rates pre-implantation and post-im
Pre-implantation (ml/s) Post-im
A Left (n = 12) 25.38 ± 5.50
Right (n = 12) 21.30 ± 5.41
B Left (n = 12) 27.71 ± 6.28
Right (n = 12) 22.37 ± 4.85
A: the new type of aortic valved stent released within the native valve leaflets; B: th
coronary flow rates pre-implantation VS post-implantation, *P < 0.05.22.37 ± 4.85 ml/s to 21.73 ± 4.77 ml/s (P = 0.1487) with
no significant difference when the new type of aortic
valved stents were released in ascending aorta.
Furthermore, there was no significant difference in the
transvalvular pressure gradient and effective orifice area
of the new valved stents implanted within the native
valve leaflets or in the ascending aorta (P > 0.05, Table 2).
The transvalvular pressure gradients of the new valved
stents implanted within the valve leaflets or in the as-
cending aorta were less than 1.33 Kpa (10 mmHg), and
the effective orifice area was about 1 cm2 under the flow
rate of 5 L/min (Table 2). Therefore, the opening of new
valved stents could not be affected by valve leaflets.
The post-implantation aortic regurgitant volumes under
different pressures were obviously reduced (P < 0.05,
Table 3). There was no significant difference in static leak-
age between the old and new valved stents under different
pressures (P > 0.05, Table 4). The perivalvular leakages
of new valved stents under 60, 80, and 100 mmHg were
obviously lower than those of the old stents (P < 0.05,
Table 4).
Implantation of aortic valved stent in vivo
The implantation of aortic valved stent was successfully
performed in six pigs using retrograde implantation ap-
proach and no obviously adverse reaction was observed
after implantation. However, one pig was died 10 h after
the implantation since the stent was not expanded
completely. The leaflets in stents were opening well
and no valvular regurgitation was observed after suc-
cessful deployment of the stents in the other five pigs.
Furthermore, there was no apparent change in the out-
flow tract pressure, systolic and diastolic function of left
ventricle.
The other 5 pigs were euthanized 24 h post implant-
ation for anatomic evaluation. The morphological char-
acteristics of aortic valved stent were observed and most
of the stent was covered with thin layer of endothelial
cells (Figure 5). The post implantation anatomical fea-
tures of three valve leaflets of aortic valved stent were
shown in Figure 6. The aortic valved stents were fixed
well in the ascending aorta. A small amount of
fibroblast-like substances could observed in the aortic
valved stents and thrombosis was not found.plantation
plantation (ml/s) Flow rate variation (ml/s) P value
19.71 ± 4.80 5.67 ± 1.52 0.0000*
17.74 ± 4.10 3.56 ± 1.88 0.0001*
27.58 ± 6.16 0.14 ± 1.35 0.7426
21.73 ± 4.77 0.64 ± 1.36 0.1487
e new type of aortic valved stent released in the ascending aorta. The
Table 2 Comparison of transvalvular pressure gradient and effective orifice area for the new type of valved stents
implanted within the native valve leaflets or in the ascending aorta
Flow rate
(L/min)
Transvalvular pressure gradient (Kpa) P value Effective orifice area (cm2) P value
Within Ascending aorta Within Ascending aorta
1 0.64 ± 0.09 0.63 ± 0.08 0.9087 0.77 ± 0.17 0.77 ± 0.15 0.8885
2 0.69 ± 0.10 0.70 ± 0.06 0.7785 0.82 ± 0.19 0.81 ± 0.16 0.8302
3 0.75 ± 0.09 0.76 ± 0.07 0.8057 0.86 ± 0.16 0.87 ± 0.19 0.4519
4 0.80 ± 0.08 0.78 ± 0.07 0.0643 0.92 ± 0.17 0.91 ± 0.16 0.8736
5 0.86 ± 0.08 0.83 ± 0.07 0.2431 1.00 ± 0.17 0.99 ± 0.17 0.6475
6 0.90 ± 0.09 0.91 ± 0.10 0.5549 1.03 ± 0.15 1.02 ± 0.15 0.7291
7 0.93 ± 0.10 0.96 ± 0.10 0.5165 1.09 ± 0.16 1.08 ± 0.16 0.9161
8 1.04 ± 0.09 1.06 ± 0.10 0.6707 1.13 ± 0.16 1.12 ± 0.17 0.5842
9 1.10 ± 0.09 1.12 ± 0.10 0.6892 1.13 ± 0.15 1.12 ± 0.16 0.5234
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TAVI was first proposed in 1992 by Andersen and Crib-
ier reported the first clinical case of successful applica-
tion of TAVI in 2002. Two typical representative aortic
valved stents were Cribier-Edwards and CoreValve
[18,19]. The Cribier-Edwards valve is a trileaflet valve
composed of three equal sections of equine pericardium
integrated into a stainless steel balloon expandable stent
frame [20,21]. CoreValve is a self-expanding aortic valve
prosthesis intended for retrograde delivery across the
aortic valve [22,23]. It has been reported that the coronary
artery flow could be effect by aortic valved stents when
TAVI was performed in animal experiments and clinical
treatments, especially in the cases of aortic insufficiency
[24,25]. Flecher et al. have reported that implantation of a
percutaneous valved stent in the orthotopic position with
the native valve in place causes coronary ostial obstruction
[26]. This problem highlights the need for modified stents
that are designed for implantation in patients with non-
retracted, fibrotic, or calcified leaflets.
In our study, we designed a new type of aortic valve
stent according to the anatomy parameters of porcine
aortic root and porcine pericardium valves were sutured
with the distal end of self-expandable stent. The TAVI
was performed in the isolated porcine heart in vitro and
the coronary artery flow rates were measured. There wasTable 3 Comparison of aortic regurgitant volume under
different pressures between pre-implantation and
post-implantation of new valved stents
Pressure
(mmHg)
Pre-implantation (ml) Post-implantation (ml) P value
40 576.17 ± 51.71 514.83 ± 52.26 0.0193
60 703.50 ± 138.68 653.50 ± 117.14 0.0296
80 887.17 ± 150.84 791.50 ± 151.66 0.0422
100 985.34 ± 145.22 845.20 ± 132.31 0.0403
120 1243.07 ± 142.17 1095.36 ± 159.37 0.0395no significant difference in the left and right coronary
artery flow rates between pre-implantation and post-
implantation when the new type of aortic valved stents
were released in ascending aorta (P = 0.7426, P = 0.1487).
While, the left and right coronary artery flow rates de-
creased significantly after implantation when the new
type of aortic valved stents were released within the na-
tive valve leaflets (P = 0.000, P = 0.0001). However, cor-
onary ostial obstruction is mainly due to the calcification
of the aortic valve leaflet since the calcific native valve
leaflets are easily to be pressed toward the side wall by
the stents [27,28]. Quaden et al. have reported that using a
high-pressure water stream to endovascularly resect hu-
man calcified aortic valves could easily lead to thrombo-
embolism since it is hardly to capture all the tissue
fragments of disordered valves [29]. In our study, valved
stents were tested in the healthy aortic valves. Therefore,
whether the new type of aortic valve stent implanted in
the ascending aorta could avoid the impacts caused by
valve leaflets on the opening of coronary artery need to be
further studied. No obvious shifting was observed when
the new type of aortic valved stent was released within the
native valve leaflets suggesting that the special shape of
our aortic valved stent increased the stability at the
aortic root. Therefore, a better stability of stent could
be obtained when the aortic valve stent was implanted in
ascending aorta.
TAVI is usually performed using the antegrade or
retrograde implantation approach. Currently, the ante-
grade transseptal approach has been adopted in most
cases. Cribier et al. have successfully performed the
TAVI in patients with end-stage calcific aortic stenosis
using the antegrade transseptal approach [10,27]. Boud-
jemline et al. performed retrograde replacement on the
carotid artery of lamb which resulted in many complica-
tions including obstruction of coronary sinus, mitral in-
sufficiency and stent shifting [30]. However, the efficacy
of antegrade implantation approach for patients with
Table 4 Comparison of the static leakage and perivalvular leakage for the old and new valved stents under different
pressures
Pressure (mmHg) Valved stents (n = 6) Total regurgitation (ml) Static leakage (ml) Perivalvular leakage (ml)
40
Old 322.00 ± 57.30 151.50 ± 24.52 170.50 ± 41.28
New 319.67 ± 59.61 135.83 ± 29.96 183.83 ± 47.62
P value 0.9558 0.2943 0.6898
60
Old 511.50 ± 48.71 218.83 ± 32.82 292.67 ± 66.27
New 476.17 ± 51.71 228.83 ± 38.97 247.33 ± 56.15
P value 0.1190 0.6007 0.0220*
80
Old 700.17 ± 134.90 308.17 ± 84.37 392.00 ± 87.79
New 654.50 ± 120.09 306.33 ± 93.18 331.50 ± 77.77
P value 0.0195* 0.9205 0.0260*
100
Old 875.83 ± 170.19 358.17 ± 88.48 517.67 ± 117.83
New 760.17 ± 129.37 346.50 ± 87.20 413.67 ± 100.39
P value 0.0301* 0.2045 0.0373*
120
Old 1065.67 ± 149.71 399.17 ± 82.87 666.50 ± 114.87
New 1035.00 ± 140.59 404.17 ± 83.56 630.83 ± 101.45
P value 0.3376 0.7375 0.3969
*P < 0.05, new aortic valved stents compared with the old stents.
Figure 5 The post implantation morphological characteristics of aortic valved stent and the thin layer of endothelial cells on aortic
valved stent was pointed out using white arrow.
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Figure 6 The post implantation anatomical features of three valve leaflets of aortic valved stent.
Cai et al. Journal of Cardiothoracic Surgery 2013, 8:210 Page 8 of 9
http://www.cardiothoracicsurgery.org/content/8/1/210severe heart diseases was not satisfied. Hanzel et al. re-
ported that retrograde implantation was successfully
conducted in a stable position for an 84-year-old man
with critical aortic stenosis and refractory congestive
heart failure, while many difficulties were encountered
with an initial antegrade approach [31]. Webb et al. re-
ported that the aortic valve area was significantly in-
creased, no intraprocedural deaths, 16 patients (89%)
remained alive after follow-up of 75 ± 55 days when
TAVI was performed in 18 high risk patients (aged 81 ±
6 years) by using the retrograde implantation approach
[32]. In our study, implantation of aortic valved stents
in vivo further proved that the new type of aortic valved
stent could be implanted in the ascending aorta by the
retrograde implantation method via delivery catheter
and successfully released. However, the stent did not ex-
pand completely in one pig. Hence, the development of
shape memory functional stents which has relationship
with the manufacture of the Ni-Ti alloy stent, suture of
valves, size of stents and delivery catheter, need to be
emphasized. What’s more, pigs were euthanized 24 h
post implantation for anatomic evaluation. However, this
design might be a limitation since only one time point
was selected in our study. In our further study, we will
design a serious of time points to follow-up the efficacy
of the surgery.Conclusions
In conclusion, the new type of aortic valved stent de-
signed in this study is characterized with good stability
and has the potential to avoid the impact caused by
valve leaflets on the coronary artery. In our study, the
ascending aorta of the miniature pig was used as the ani-
mal model. However, the state of the valves in the iso-
lated heart in vitro model was different from that in the
heart of a live animal. And there must be some differ-
ences in the cardiac system between human and pigs
though the cardiac structure of pig was similar to that of
the human. Therefore, the application of aortic valved
stent in human need to be further studied.
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